Reports March 2018

 

EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl)

In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment | EMCDDA/Europol, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl)

In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment | EMCDDA/Europol, Portugal

Implementing Supervised Injection Services (PDF)

This nursingG best practice guideline (BPG) is a comprehensive document that provides an overview of principles, resources, and structures for delivering evidence-based supervised injection services (SIS). It is not intended to be a manual or “how-to” guide; rather, it supports best practices and decision making for nurses, health workersG, and health system leaders | MAO, Canada

Government response to ACMD Report: Commissioning impact on drug treatment services (PDF)

The Government thanks the ACMD for its report on commissioning structures within treatment services entitled Commissioning Structures, the Financial Environment and Wider Changes to Health and Social Welfare Impact on Drug Misuse Treatment and Recovery. The Committee made a number of recommendations for the Government to consider; the Government response is set out below | DHSC, UK

CLeaR local tobacco control assessment

Guidance for local authorities, public health bodies and the NHS on using ‘deep dive’ self-assessment tools to improve their tobacco control work | PHE, UK

Adfam's 2017 impact report

Today we are pleased to launch our impact report for 2017! This document provides an overview of our work with families, practitioners and strategic partners | Adfam, UK

Our Invisible Addicts (2nd edition)

The publication of Our Invisible Addicts in 2011 represented an important landmark in recognising the extent of substance-related health problems amongst older people and that the special service needs to deal with the complexity of such problems, which often involve co-morbid mental and physical health problems, polypharmacy and psychosocial adversity | RC PSYCH, UK

The misuse of synthetic opioids: harms and clinical management of fentanyl, fentanyl analogues and other novel synthetic opioids (PDF)

This document focuses on the misuse of fentanyl, fentanyl analogues and other novel synthetic opioids and does not address issues pertaining to their use in legitimate therapeutic and clinical contexts. Specifically, this document focuses on the clinical management of the health-related harms associated with the misuse of these substances, both acute harms as well as harms from frequent and long-term use (chronic harms). It is aimed primarily at a clinical audience | Neptune, UK

The Death Penalty for Drug Offences: Global Overview 2017

Our Global Overview series monitors the death penalty for drugs in law and practice worldwide, and also considers critical developments on the issue. Since being launched in 2007, Harm Reduction International's death penalty work has been the leading global resource on the issue of the death penalty for drug offences | HRI, UK

Statistics on Women's Smoking Status at Time of Delivery, England - Quarter 3, 2017-18

This report presents the latest results and trends from the women's smoking status at time of delivery (SATOD) data collection in England. A new interactive tool has been published which allows users to select and view information for individual Clinical Commissioning Groups | NHS Digital, UK

Balancing Treaty Stability and Change: Inter se modification of the UN drug control conventions to facilitate cannabis regulation (PDF)

The drug policy landscape is in a process of profound change, most notably with more and more countries moving towards a legal regulation of the cannabis market. This reality is increasing legal tensions within the international drug control regime, an almost universally accepted treaty-based system currently built on a suite of three UN treaties agreed | WOLA, TNI, GDPO, UK

Statistics on Women's Smoking Status at Time of Delivery, England - Quarter 3, 2017-18

This report presents the latest results and trends from the women's smoking status at time of delivery (SATOD) data collection in England. A new interactive tool has been published which allows users to select and view information for individual Clinical Commissioning Groups | NHS Digital, UK

Tax treatment of heated tobacco products: response to the consultation (PDF)

Summary of responses and next steps | HM Treasury, UK

Hepatitis B: vaccine recommendations during supply constraints

[Vaccine supplies are improving but remain constrained. The vaccine remains available for those at highest risk of exposure, including those who inject drugs. PHE has recently published a recovery plan to support re-introduction of the vaccine for lower priority groups in a phased approach to maintain continuity of supply. Commissioners and providers of drug services are advised to read the plan noting that they can now order larger volumes of vaccine, likely without need for an override request] | PHE, UK

Night Lives: Reducing Drug-Related Harm in the Night Time Economy

The UK’s night time economy is failing to protect its most valuable asset: the people who go out and enjoy it. Night Lives: Reducing Drug-Related Harm in the Night Time Economy, a joint report by the All-Party Parliamentary Group for Drug Policy Reform, Durham University, The Loop and Volteface, advocates for the adoption of a set of bold yet practical initiatives across our towns and cities to address this failure. Aimed at stakeholders including the night time industry, local authorities, police forces and public health, Night Lives offers new ideas for reducing drug-related harm in the UK’s night time economy | Volte Face, Durham University, We are the loop, APPG on drug policy reform, UK

Eliminating Hepatitis C in England (PDF)

Over the course of this inquiry into eliminating hepatitis C, the APPG on Liver Health has heard from experts engaged in every aspect of the hepatitis C care pathway. Our contributors have included patients, leading clinicians, NHS managers, commissioners, third sector service workers, campaigners, senior pharmaceutical industry representatives and national public health policy leads. Without exception, they told us that England will not fulfil its commitment to elimination of hepatitis C by 2030 unless the number of people diagnosed and initiated onto treatment is greatly increased | All-Party Parliamentary Group on Liver Health, UK

Changing Lives: using peer support to promote access to services for family members affected by someone else’s drug or alcohol use

Over the last five years, we have worked with families affected by drugs and alcohol in Greenwich to provide them with the training, resources and support to understand the impact of drugs and alcohol on their lives, and to build sustainable relationships and positive futures | Adfam, UK

Inquiry into drug law reform (PDF)

While the title of the inquiry relates specifically to law reform, the Committee’s investigations were largely informed by the evidence received in submissions and public hearings, which called for a broader examination of drug-related laws, policies, procedures, programs and initiatives. The result is a report that comprehensively explored the key areas of prevention, law enforcement, treatment and harm reduction, and acknowledges the need for a more effective drug response framework, one that prioritises health and community safety | Victorian Government, Australia

Global review of drug checking services operating in 2017

Drug checking (or 'pill testing') services invite members of the public to anonymously submit psychoactive drug samples for forensic analysis and then provide individualised feedback of results and counselling as appropriate | NDARC, Australia

Deaths related to volatile substances and helium in Great Britain: 2001 to 2016 registrations

Deaths related to volatile substances and helium in England, Wales and Scotland from 2001 to 2016, by region, sex, age, substances involved and cause of death | ONS, UK

Hepatitis C in England 2018 report (PDF)

In this report, we summarise the impact of action plans in England to drive down mortality from HCV, reduce the number of new infections, and outline the actions required to make further progress | PHE, UK

Hepatitis C in the North West: annual review

Hepatitis C in the North West is still a major public health concern, however, rates since 2014 have remained stable. Estimates suggest at least 40,000 people across the North West acquired hepatitis C infection, and of those 27,000 have developed chronic infection | PHE, UK

Sligo city alcohol strategy. Prevent & reduce alcohol related harm 2018 – 2023 (PDF)

This five-year strategy has been developed to prevent and reduce alcohol-related harm in Sligo City. It is informed by research on effective approaches to tackling alcohol-related harm and focuses on four key areas | Northwest Regional Drug and Alcohol Taskforce, Ireland

Opiate and crack cocaine use: prevalence estimates for local populations

Estimates of the number of opiate and crack cocaine users in local areas from 2014 to 2015 | PHE, UK

Estimates of the number of children who live with opiate users, England 2014/15 (PDF)

Information from the National Drug Treatment Monitoring System (NDTMS) has been combined with estimates of the number of opiate users in England (in 2014/15)2 to provide estimates of the number of children who may be considered as ‘affected by parental opiate use’ | PHI, UK

Stop smoking interventions and services

This guideline covers stop smoking interventions and services delivered in primary care and community settings for everyone over the age of 12. It aims to ensure that everyone who smokes is advised and encouraged to stop and given the support they need. It emphasises the importance of targeting vulnerable groups who find smoking cessation hard or who smoke a lot. News article here | NICE, UK

Impact of alcohol and illicit drug use on the burden of disease and injury in Australia: Australian Burden of Disease Study 2011

This report quantifies the health impact that alcohol and illicit drug use place on Australia, including as risk factors for other diseases and injuries. It estimates that alcohol and illicit drugs were collectively responsible for 6.7% of Australia’s disease burden in 2011. The report highlights that health inequalities exist, with lower socioeconomic groups and more remote areas generally experiencing higher rates of disease burden due to alcohol and illicit drug use | AIHW, Australia